Pulse Biosciences (NASDAQ:PLSE – Free Report) had its target price boosted by Canaccord Genuity Group from $58.00 to $74.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.
PLSE has been the subject of a number of other research reports. Needham & Company LLC lifted their price target on Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Freedom Capital upgraded Pulse Biosciences to a “strong-buy” rating in a research note on Wednesday, September 9th. Oppenheimer raised their price objective on Pulse Biosciences from $35.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, October 13th. Finally, BTIG Research began coverage on Pulse Biosciences in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $66.60.
View Our Latest Stock Report on PLSE
Pulse Biosciences Stock Performance
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Pulse Biosciences had a negative return on equity of 101.91% and a negative net margin of 5,603.88%. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.52 million. During the same quarter in the previous year, the company posted ($0.29) EPS. The business’s revenue was down 54.1% on a year-over-year basis. On average, equities research analysts forecast that Pulse Biosciences will post -1.34 EPS for the current year.
Insiders Place Their Bets
In related news, COO Liane Teplitsky bought 1,036 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the transaction, the chief operating officer owned 1,036 shares in the company, valued at $49,966.28. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders acquired 4,095 shares of company stock valued at $199,931. 74.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Pulse Biosciences
A number of large investors have recently bought and sold shares of PLSE. Osterweis Capital Management Inc. bought a new position in Pulse Biosciences in the second quarter valued at about $28,000. Sterling Capital Management LLC increased its stake in shares of Pulse Biosciences by 844.6% in the third quarter. Sterling Capital Management LLC now owns 614 shares of the company’s stock valued at $31,000 after buying an additional 549 shares during the period. Jupiter Topco LLC acquired a new position in shares of Pulse Biosciences in the second quarter valued at approximately $241,000. Axxcess Wealth Management LLC bought a new position in Pulse Biosciences in the 3rd quarter valued at approximately $242,000. Finally, GSA Capital Partners LLP bought a new position in Pulse Biosciences in the 2nd quarter valued at approximately $290,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.
Key Pulse Biosciences News
Here are the key news stories impacting Pulse Biosciences this week:
- Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
- Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
- Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
- Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
- Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage
About Pulse Biosciences
See Also
- Five stocks we like better than Pulse Biosciences
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
